Ekkehard Schütz

Direttore Tecnico/Scientifico/R&S presso ONCOCYTE CORPORATION

Patrimonio netto: - $ in data 30/06/2024

Health Technology

Consumer Services

Profilo

Ekkehard Schütz is currently the Chief Executive Officer & Chief Medical Officer at Chronix Biomedical, Inc. He is also the Managing Director at Chronix Biomedical GmbH since 2011.
Additionally, he holds the position of Chief Science Officer at OncoCyte Corp.
starting from 2021.
Dr. Schütz obtained his doctorate degree from the University of Gottingen.

Partecipazioni note in società pubbliche

Società	Data	Numero di azioni	Valorizzazione	Data di valutazione
ONCOCYTE CORPORATION -.--%	29/04/2024	0 ( -.--% )	- $	30/06/2024

Posizioni attive di Ekkehard Schütz

Società	Posizione	Inizio
ONCOCYTE CORPORATION	Direttore Tecnico/Scientifico/R&S	01/04/2021
Chronix Biomedical, Inc. Chronix Biomedical, Inc. Medical SpecialtiesHealth Technology Chronix Biomedical, Inc. manufactures diagnostic substances chemicals. It develops DNA-based blood tests primarily for monitoring minimal residual disease in cancer patients. The firm also develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood and central nervous system. The company was founded by Wiiliam A. Boeger and Howard B. Urnovitz in 1997 and is headquartered in San Jose, CA.	Amministratore Delegato	-
Chronix Biomedical GmbH	Corporate Officer/Principal	01/04/2011

Tutte le posizioni attive di Ekkehard Schütz

Formazione di Ekkehard Schütz

University of Gottingen

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Ekkehard Schütz

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
ONCOCYTE CORPORATION	Health Technology

Aziende private	2
Chronix Biomedical, Inc. Chronix Biomedical, Inc. Medical SpecialtiesHealth Technology Chronix Biomedical, Inc. manufactures diagnostic substances chemicals. It develops DNA-based blood tests primarily for monitoring minimal residual disease in cancer patients. The firm also develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood and central nervous system. The company was founded by Wiiliam A. Boeger and Howard B. Urnovitz in 1997 and is headquartered in San Jose, CA.	Health Technology
Chronix Biomedical GmbH